Seek Returns

BNTX vs. KYMR: BioNTech vs. Kymera Therapeutics Stock Comparison

How do BioNTech (BNTX) and Kymera Therapeutics (KYMR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

BioNTech (BNTX) and Kymera Therapeutics (KYMR) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Kymera Therapeutics (KYMR) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Company profile comparison for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
Profile ItemBNTXKYMR
NameBioNTech SE American Depositary ShareKymera Therapeutics Inc.
Country/RegionGermanyUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization21.70 billion USD11.25 billion USD
CurrencyUSDUSD
ExchangeNasdaqNasdaq
Listing DateOctober 10, 2019August 21, 2020
Security TypeADRCommon Stock

Price Performance

Cumulative Growth

BNTX
KYMR
GSPC
Loading price history…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for BioNTech (BNTX) and Kymera Therapeutics (KYMR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for BioNTech (BNTX) and Kymera Therapeutics (KYMR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Total Return (1Y)-14.78%131.52%
Total Return (3Y, Annualized)-3.99%111.65%
Total Return (5Y, Annualized)-17.02%15.68%

Risk Profile

Drawdown History

BNTX
KYMR
GSPC
Loading price history…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for BioNTech (BNTX) and Kymera Therapeutics (KYMR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Volatility (1Y, Annualized)47.44%62.83%
Beta (5Y)1.302.00
Max Drawdown (5Y)-78.10%-83.27%
Avg. Volume (3M)1.21M833.05K

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BNTX and KYMR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Sharpe Ratio (1Y)-0.402.03
Sortino Ratio (1Y)-0.594.16

Profitability

ROE (TTM)

Both BioNTech (BNTX) at -8.14% and Kymera Therapeutics (KYMR) at -27.29% report negative ROE values. Negative ROE can reflect losses or negative shareholders’ equity, so both readings need extra context.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-8.14%

Max
109.18%
Q3
6.23%
BNTX
-8.14%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-27.29%

Max
109.18%
Q3
6.23%
Median
-26.66%
KYMR
-27.29%
Q1
-64.05%
Min
-167.77%
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Kymera Therapeutics (KYMR) reports 0.00%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

-60.87%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BNTX
-60.87%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Max
18.05%
Q3
4.78%
KYMR
0.00%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile BioNTech (BNTX) reports 30.28%, ranking against industry peers normally.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

30.28%

Max
83.12%
BNTX
30.28%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

-396.04%

Max
83.12%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
KYMR
-396.04%
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
ROE (TTM)-8.14%-27.29%
ROA (TTM)-4.04%-17.64%
Net Margin (TTM)-60.87%0.00%
Operating Margin (TTM)30.28%-396.04%
Gross Margin (TTM)76.73%0.00%

Growth

Revenue Growth

BioNTech (BNTX) at 4.32% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Neither BioNTech (BNTX) nor Kymera Therapeutics (KYMR) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Growth metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Revenue Growth (YoY)4.32%-16.70%
Revenue Growth (3Y CAGR)-45.06%-5.74%
EPS Growth (YoY)----
EPS Growth (3Y CAGR)----

Financial Strength

Current Ratio (MRQ)

Both BioNTech (BNTX) at 8.55 and Kymera Therapeutics (KYMR) at 11.13 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.55

Max
25.13
Q3
12.13
BNTX
8.55
Median
5.52
Q1
2.47
Min
0.10

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

11.13

Max
25.13
Q3
12.13
KYMR
11.13
Median
5.52
Q1
2.47
Min
0.10
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

BioNTech (BNTX) at 0.02 keeps leverage in the lower industry quartile, while Kymera Therapeutics (KYMR) at 0.05 runs a more typical debt-to-equity mix.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.02

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
BNTX
0.02
Min
0.00

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.05

Max
1.42
Q3
0.65
Median
0.15
KYMR
0.05
Q1
0.02
Min
0.00
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Current Ratio (MRQ)8.5511.13
Debt / Equity (MRQ)0.020.05
Net Debt / EBITDA----

Dividends

Dividend Yield (TTM)

Neither BioNTech (BNTX) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither BioNTech (BNTX) nor Kymera Therapeutics (KYMR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BNTX
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

KYMR
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%0.00%

Valuation

P/E Ratio (TTM)

Neither BioNTech (BNTX) nor Kymera Therapeutics (KYMR) reports a P/E ratio value for this period, so a direct comparison isn’t possible.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BNTX
--

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
KYMR
--
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): Neither stock reports P/E ratio, so the chart shows available benchmark boxes without value markers.

P/S Ratio (TTM)

BioNTech (BNTX) at 8.96 prices around its industry’s typical P/S ratio, while Kymera Therapeutics (KYMR) at 110.00 clears its benchmark range — KYMR looks notably rich on sales.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.96

Max
58.18
Q3
25.77
BNTX
8.96
Median
7.30
Q1
3.01
Min
0.01

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

110.00

KYMR
110.00
Max
58.18
Q3
25.77
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

BioNTech (BNTX) at 1.09 looks cheap against book in the lower P/B ratio quartile, while Kymera Therapeutics (KYMR) at 6.96 carries a premium in the upper quartile — a clear price-to-book gap.

BNTX

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.09

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BNTX
1.09
Min
-5.59

KYMR

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.96

Max
13.53
KYMR
6.96
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
BioNTech (BNTX) vs. Kymera Therapeutics (KYMR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for BioNTech (BNTX) and Kymera Therapeutics (KYMR)
MetricBNTXKYMR
P/E Ratio (TTM)----
P/S Ratio (TTM)8.96110.00
P/B Ratio (MRQ)1.096.96
Free Cash Flow Yield (TTM)-7.34%-1.46%